Ember Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

Ember Therapeutics is a small biotechnology company based in Watertown, Massachusetts. It focuses on translating advances in brown fat biology and the mechanisms behind selective insulin sensitivity into a pipeline of therapies that act peripherally to address metabolic diseases, including type 2 diabetes and obesity. The work is product-oriented, aiming to move from biological insight to treatments for metabolic conditions.

The company operates within the biotechnology research industry and targets researchers and organizations pursuing new approaches to metabolic illness. In August 2018, Ember Therapeutics announced the sale of its OP-1 product family and related assets to Viscogliosi Brothers LLC, marking a notable recent development. Previously, Ember had acquired the exclusive worldwide license to BMP-7 and the OP-1 portfolio from Stryker in 2014, highlighting its long-standing focus on insulin sensitivity and related biology.

Sign up for free to view info

Company overview Employee directory